000403 派林生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.4799.7098.5638.90110.727
总资产报酬率 ROA (%)3.7958.3387.3697.7928.921
投入资产回报率 ROIC (%)4.0368.9747.9998.4899.918

边际利润分析
销售毛利率 (%)46.31849.13251.48152.12746.072
营业利润率 (%)26.66433.16129.85327.58323.351
息税前利润/营业总收入 (%)23.43830.27127.07725.15720.907
净利润/营业总收入 (%)22.09328.06526.25824.43419.858

收益指标分析
经营活动净收益/利润总额(%)101.73598.379100.16398.707105.739
价值变动净收益/利润总额(%)2.5302.828-1.6811.20617.010
营业外收支净额/利润总额(%)-6.027-3.229-1.029-0.460-0.528

偿债能力分析
流动比率 (X)2.9343.7403.7153.1763.845
速动比率 (X)1.5892.4512.7292.5262.694
资产负债率 (%)16.25114.37114.00414.04610.724
带息债务/全部投入资本 (%)10.8877.1905.9874.5111.270
股东权益/带息债务 (%)811.1951,279.6641,551.4232,083.6397,632.613
股东权益/负债合计 (%)515.798596.391614.644612.517832.250
利息保障倍数 (X)-13.707-16.344-10.952-10.939-9.005

营运能力分析
应收账款周转天数 (天)106.42782.369109.718102.62274.207
存货周转天数 (天)460.671285.599244.231213.018199.877